{"id":31329,"date":"2019-02-12T12:00:00","date_gmt":"2019-02-12T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\/"},"modified":"2019-02-12T12:00:00","modified_gmt":"2019-02-12T12:00:00","slug":"herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/de\/news\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\/","title":{"rendered":"Herausforderungen und Strategien f\u00fcr die Einf\u00fchrung von Biologika"},"content":{"rendered":"<div class=\"paragraph paragraph--text-columns paragraph-id--1469 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<h2>Rhinology Future Debates Br\u00fcssel 2018<\/h2>\n<p>Prof. Dr. Claus Bachert pr\u00e4sentiert Strategien f\u00fcr die Einf\u00fchrung der biologischen Behandlung bei Patienten mit CRSwNP und integrierte Versorgungspfade f\u00fcr CRS. Zudem erl\u00e4utert er Behandlungsm\u00f6glichkeiten und die Definition von Patienten, die mit monoklonalen Antik\u00f6rpern behandelt werden sollten. <\/p>\n<h3>Podiumsteilnehmende<\/h3>\n<p>Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, Patientenvertreter.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"paragraph paragraph--text-columns paragraph-id--1470 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<div class=\"video-container\"><center><iframe title=\"YouTube-Videoplayer\" src=\"https:\/\/www.youtube.com\/embed\/oKJ506sZiAY?rel=0\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/center><\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Rhinology Future Debates Br\u00fcssel 2018 Prof. Dr. Claus Bachert pr\u00e4sentiert Strategien f\u00fcr die Einf\u00fchrung der biologischen Behandlung bei Patienten mit CRSwNP und integrierte Versorgungspfade f\u00fcr CRS. Zudem erl\u00e4utert er Behandlungsm\u00f6glichkeiten und die Definition von Patienten, die mit monoklonalen Antik\u00f6rpern behandelt werden sollten. Podiumsteilnehmende Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, Patientenvertreter.<\/p>\n","protected":false},"author":1,"featured_media":31346,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[182],"tags":[157,160,162,183,184,185,186],"class_list":["post-31329","news","type-news","status-publish","has-post-thumbnail","hentry","category-rhinology-future-debates","tag-chronische-rhinosinusitis-crs","tag-crswnp","tag-gesundheitsfachkrafte","tag-rhinologie","tag-debatten","tag-rhinology-future-debates","tag-biologika"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Herausforderungen und Strategien f\u00fcr die Einf\u00fchrung von Biologika - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/de\/news\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Herausforderungen und Strategien f\u00fcr die Einf\u00fchrung von Biologika\" \/>\n<meta property=\"og:description\" content=\"Rhinology Future Debates Br\u00fcssel 2018 Prof. Dr. Claus Bachert pr\u00e4sentiert Strategien f\u00fcr die Einf\u00fchrung der biologischen Behandlung bei Patienten mit CRSwNP und integrierte Versorgungspfade f\u00fcr CRS. Zudem erl\u00e4utert er Behandlungsm\u00f6glichkeiten und die Definition von Patienten, die mit monoklonalen Antik\u00f6rpern behandelt werden sollten. Podiumsteilnehmende Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, Patientenvertreter.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/de\/news\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\\\/\",\"name\":\"Herausforderungen und Strategien f\u00fcr die Einf\u00fchrung von Biologika - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_16.png\",\"datePublished\":\"2019-02-12T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\\\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_16.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_16.png\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/waehlen-sie-ihren-weg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Herausforderungen und Strategien f\u00fcr die Einf\u00fchrung von Biologika\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Herausforderungen und Strategien f\u00fcr die Einf\u00fchrung von Biologika - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/de\/news\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\/","og_locale":"de_DE","og_type":"article","og_title":"Herausforderungen und Strategien f\u00fcr die Einf\u00fchrung von Biologika","og_description":"Rhinology Future Debates Br\u00fcssel 2018 Prof. Dr. Claus Bachert pr\u00e4sentiert Strategien f\u00fcr die Einf\u00fchrung der biologischen Behandlung bei Patienten mit CRSwNP und integrierte Versorgungspfade f\u00fcr CRS. Zudem erl\u00e4utert er Behandlungsm\u00f6glichkeiten und die Definition von Patienten, die mit monoklonalen Antik\u00f6rpern behandelt werden sollten. Podiumsteilnehmende Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, Patientenvertreter.","og_url":"https:\/\/www.euforea.org\/de\/news\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","twitter_card":"summary_large_image","twitter_site":"@euforea","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/de\/news\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\/","url":"https:\/\/www.euforea.org\/de\/news\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\/","name":"Herausforderungen und Strategien f\u00fcr die Einf\u00fchrung von Biologika - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/de\/news\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/de\/news\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_16.png","datePublished":"2019-02-12T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/de\/news\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/de\/news\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.euforea.org\/de\/news\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_16.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_16.png","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/de\/news\/herausforderungen-und-strategien-fuer-die-einfuehrung-von-biologika\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.euforea.org\/de\/waehlen-sie-ihren-weg\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/de\/news\/"},{"@type":"ListItem","position":3,"name":"Herausforderungen und Strategien f\u00fcr die Einf\u00fchrung von Biologika"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/de\/#website","url":"https:\/\/www.euforea.org\/de\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/de\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/de\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.euforea.org\/de\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/news\/31329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/comments?post=31329"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/news\/31329\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/media\/31346"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/media?parent=31329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/categories?post=31329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/de\/wp-json\/wp\/v2\/tags?post=31329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}